Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II–IIIc breast cancer

XeNA: Capecitabine Plus Docetaxel, With or Without Trastuzumab, as Preoperative Therapy for Early Breast Cancer

(2012) Stefan Glück et al.   International Journal of Medical Sciences

Catalase overexpression in mammary cancer cells leads to a less aggressive phenotype and an altered response to chemotherapy

(2011) Christophe Glorieux et al.   BIOCHEMICAL PHARMACOLOGY

Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13

(2011) Rachel F. Gabitass et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Cellular Redox Pathways as a Therapeutic Target in the Treatment of Cancer

(2011) Alberto J. Montero et al.   DRUGS

Selective targeting of breast cancer cells through ROS-mediated mechanisms potentiates the lethality of paclitaxel by a novel diterpene, gelomulide K

(2011) Juan-Cheng Yang et al.   FREE RADICAL BIOLOGY AND MEDICINE

The role of glutathione S-transferase P in signaling pathways and S-glutathionylation in cancer

(2011) Kenneth D. Tew et al.   FREE RADICAL BIOLOGY AND MEDICINE

The Relevance of Breast Cancer Subtypes in the Outcome of Neoadjuvant Chemotherapy

(2010) M. E. Straver et al.   ANNALS OF SURGICAL ONCOLOGY

Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity

(2010) Suzanne Ostrand-Rosenberg   CANCER IMMUNOLOGY IMMUNOTHERAPY

DCPIP (2,6-dichlorophenolindophenol) as a genotype-directed redox chemotherapeutic targeting NQO1*2 breast carcinoma

(2010) Christopher M. Cabello et al.   FREE RADICAL RESEARCH

Changes in Dendritic Cell Phenotype After a New High-dose Weekly Schedule of Interleukin-2 Therapy for Kidney Cancer and Melanoma

(2010) Steven E. Finkelstein et al.   JOURNAL OF IMMUNOTHERAPY

Redox-Directed Cancer Therapeutics: Molecular Mechanisms and Opportunities

(2009) Georg T. Wondrak   ANTIOXIDANTS & REDOX SIGNALING

IL4Rα + Myeloid-Derived Suppressor Cell Expansion in Cancer Patients

(2009) Susanna Mandruzzato et al.   JOURNAL OF IMMUNOLOGY

Cell Cycle Regulation by Oncogenic Tyrosine Kinases in Myeloid Neoplasias: From Molecular Redox Mechanisms to Health Implications

(2008) Margret S. Rodrigues et al.   ANTIOXIDANTS & REDOX SIGNALING

Redox Regulation of Cell Survival

(2008) Dunyaporn Trachootham et al.   ANTIOXIDANTS & REDOX SIGNALING

Pharmacology of a mimetic of glutathione disulfide, NOV-002

(2008) Danyelle M. Townsend et al.   BIOMEDICINE & PHARMACOTHERAPY

A prospective study of genetic polymorphism in MPO, antioxidant status, and breast cancer risk

(2008) Chunyan He et al.   BREAST CANCER RESEARCH AND TREATMENT

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy

(2008) C. Marcela Diaz-Montero et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

NOV-002, a Glutathione Disulfide Mimetic, as a Modulator of Cellular Redox Balance

(2008) D. M. Townsend et al.   CANCER RESEARCH

Lymphopenia Associated with Adjuvant Anthracycline/Taxane Regimens

(2008) Sara M. Tolaney et al.   Clinical Breast Cancer

Immunogenic cancer cell death: a key-lock paradigm

(2008) Antoine Tesniere et al.   CURRENT OPINION IN IMMUNOLOGY

NOV-002, a mimetic of glutathione disulfide

(2008) Danyelle M Townsend et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Proper inference from Simon's two‐stage designs

(2007) Tatsuki Koyama et al.   STATISTICS IN MEDICINE